To evaluate miRNA expression level potential in CRC prognosis and their use as markers of recurrence, Pesta et al. [54] quantified Carcinoembryonic Antigen (CEA), Carbohydrate Antigen 19-9 (CA19-9), and miRNAs in pre- and postoperative blood plasma samples of CRC patients and during follow-up. The gene discussed is CEACAM5; the disease is colorectal carcinoma.